2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence

Background

Docetaxel and cabazitaxel prolong survival in mCRPC however less is known about their utilisation patterns and impact in the setting of androgen receptor-targeted agents (ARTAs; abiraterone and enzalutamide). We evaluated whether receipt of chemotherapy is associated with better survival in pts with mCRPC.

Methods

Optum^® de-identified Electronic Health Record dataset was used to identify pts with mCRPC who received first-line docetaxel or an ARTA between 01/05/11 and 30/09/17, followed by chemotherapy (docetaxel, cabazitaxel) and/or ARTA. Pts receiving chemotherapy in ≥ 1 line of treatment (any chemotherapy) vs pts not receiving chemotherapy in any treatment line (no chemotherapy) were assessed. Overall survival (OS) was calculated from start of first-line mCRPC treatment until death from any cause.

Results

In total, 1,961 pts were identified (any chemotherapy 823; no chemotherapy 1,138). Some baseline characteristics differed numerically between treatment groups. Chemotherapy-treated pts had a younger median age, greater pain medication utilisation, more metastases (including liver and lung) and a higher comorbidity score, compared with pts not receiving chemotherapy (Table). For any vs no chemotherapy, median OS was 25.4 months (95% CI 22.3–27.4 ) vs 22.4 months (95% CI 20.4–25.0 ) and the respective 12- and 24-month survival rates were 77.2% (95% CI 0.74–0.80) vs 71.3% (95% CI 0.68–0.74) and 52.1% (95% CI 0.48–0.56) vs 47.4% (95% CI 0.44–0.51).Table:

856P

Conclusions

In this real-world data analysis, less than half of pts with mCRPC received chemotherapy. Pts receiving chemotherapy were younger but had more reported metastases and comorbidities, and were more frequently prescribed pain medication. Despite these higher risk disease characteristics, median OS was observed to be higher in pts receiving any vs no chemotherapy.

Clinical trial identification

Editorial acknowledgement

Danielle Lindley and Mark Cockerill, Meditech Media.

Legal entity responsible for the study

The authors.

Funding

Sanofi.

Disclosure

A.K. Morgans: Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Bayer; Honoraria (self): Sanofi; Honoraria (self): Janssen; Honoraria (self): Genentech. H.A. Divan: Full / Part-time employment: Sanofi. A.J. Birtle: Advisory / Consultancy: Janssen; Advisory / Consultancy, Non-remunerated activity/ies: Astellas; Advisory / Consultancy, Non-remunerated activity/ies: Bayer; Advisory / Consultancy: Sanofi Genzyme; Advisory / Consultancy, Non-remunerated activity/ies: Roche; Advisory / Consultancy: MSD; Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: Ferring; Non-remunerated activity/ies: Sanofi. T. Dorff: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Janssen; Speaker Bureau / Expert testimony: Exelixis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Prometheus; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche. A. Ozatilgan: Full / Part-time employment: Sanofi. J.N. Graff: Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Sanofi; Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Advisory / Consultancy, Research grant / Funding (self): Astellas/Pfizer; Research grant / Funding (self), Investigator initiated trial funding: Janssen; Honoraria (self), Expert witness testimony: Bergman Draper Oslund; Honoraria (self), CME activity: i3 Health.